Home » Sunovion Earns Breakthrough Designation for Schizophrenia Treatment
Sunovion Earns Breakthrough Designation for Schizophrenia Treatment
May 17, 2019
Sunovion received a breakthrough therapy designation from the FDA for its investigational EP-363856 for the treatment of patients with schizophrenia.
The company believes the drug has the potential to be the first agent for the treatment of schizophrenia that is not a dopamine 2 receptor antagonist.
In Phase 2 studies, patients treated with SEP-363856 showed statistically significant improvement compared with those who received the placebo and the treatment was generally well tolerated.
Upcoming Events
-
21Oct